US 12,466,880 B2
Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma
Bongcheol Kim, Seongnam-si (KR); Dong Sik Kim, Seoul (KR); and Soon-gu Kwon, Seoul (KR)
Assigned to Neuracle Science Co., Ltd., Seoul (KR)
Filed by Neuracle Science Co., Ltd., Seoul (KR)
Filed on Jul. 27, 2023, as Appl. No. 18/360,143.
Application 18/360,143 is a division of application No. 16/626,630, granted, now 11,746,149, previously published as PCT/IB2018/054782, filed on Jun. 27, 2018.
Claims priority of provisional application 62/582,889, filed on Nov. 7, 2017.
Claims priority of provisional application 62/525,639, filed on Jun. 27, 2017.
Prior Publication US 2024/0182555 A1, Jun. 6, 2024
Int. Cl. A61K 48/00 (2006.01); C07K 16/24 (2006.01)
CPC C07K 16/24 (2013.01) [A61K 48/00 (2013.01); A61K 48/0058 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01)] 18 Claims
 
1. A method for treating a glaucoma in a subject in need thereof comprising administering to the subject a polynucleotide encoding an antibody, or an antigen binding portion thereof, that specifically binds to a family with sequence similarity 19, member A5 (FAM19A5) protein (anti-FAM19A5 antibody), wherein the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3, and wherein:
(i) the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequence set forth in SEQ ID NOs: 11, 12, and 13, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequence set forth in SEQ ID NOs: 23, 24, and 25, respectively;
(ii) the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 14, 15, and 16, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 26, 27, and 28, respectively;
(iii) the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 17, 18, and 19, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively; or
(iv) the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 20, 21, and 22, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequences set forth in SEQ ID NOs: 32, 33, and 34, respectively.